Amber Therapeutics Closes $100M Series A Financing to Advance Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence

The UK-based Amber Therapeutics has closed Series A financing of $100 million (£80 million) led by New Enterprise Associates (NEA) and with participation from new investors F-Prime Capital, Lightstone Ventures, and Intuitive Ventures and existing investors Oxford Science Enterprises (OSE) and 8VC, one of the largest Series A rounds ever in Europe for a medical technology company.

The primary focus of this funding is the development of Amber-UI, the first fully implantable adaptive neuromodulation therapy in clinical trials for women suffering from mixed urinary incontinence (MUI). Amber-UI targets the pudendal nerve through a novel, minimally invasive surgical procedure. Utilizing Amber’s Picostim System, the device can stimulate and sense physiological responses, adapting dynamically to individual needs and events. This unique capability positions Amber-UI as a potential breakthrough in neuromodulation therapy for MUI, directly regulating bladder urge and enhancing resistance to urine leakage, thus aiming to restore normal bladder function.

Aidan Crawley, CEO of Amber Therapeutics, emphasized the validation this substantial financing round provides for their therapy and team. The funds will be used to advance Amber-UI through critical pilot and pivotal studies towards regulatory approval in the US. Alongside the financing, Tiffany Le from NEA, Caroline Gaynor from Lightstone Ventures, and Kevin Chu from F-Prime have joined Amber’s Board of Directors, joining Liliane Chamas from OSE. Crawley expressed confidence in their mission to make this groundbreaking therapy accessible to millions of women suffering from MUI.


en_GBEnglish (UK)